title: CBT profiles of cabozantinib approved for advanced renal cell carcinomas.
authors.affiliation: Zhongshan Hospital Clinical Science Institute of Fudan University, Shanghai Institute of Clinical Bioinformatics, Shanghai, China. xiangdong.wang@clintransmed.org.
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Wang